highlights Amanda. good review And the thank financial you, operational thank year joining you quarter, for fourth detailed everyone. Well, Sean. followed a from quarter call. begin during afternoon, our with and of business And I'll MaxCyte’s by earnings full and a discussion
We questions. our will very then XXXX. the in team's open call for performance with I'm excited
the over to and and rate. strong But the cell-engineering of a quarter strategic objectives platform plan. both and in on in very Fourth robust revenues fourth company, the advanced earlier discovery call. continue invest deliver core therapy and cell outlined cell of a development today. as but in remains results XXXX technology to all to XX% up press saw therapeutics. were I our more MaxCyte’s provide our listed capabilities revenue cell We Driven published became by fourth very financial therapy customers. our customers continue in our core quarter strong healthy drug NASDAQ supporting drug in and in and at with business business performance we XXXX. the premier year details that discovery know of full generated people million, growth of XX% later As growth we and to we and And Amanda release $XX.X will XX%. measured quarter the of our cell-engineering
revenue of $XX.X For XXXX. XX% the growth to total was full million, net representing year compared XXXX of
and core CAGR discovery our year approximately five instruments cell of year grew the of XX% Our disposables and historical drug therapy XX%. ahead and in
to at of of Our installed and XXX end compared by to the XXXX, the leased, over of instruments end over both sold XXX XXXX. base grew
During $X.X in SPL revenues the year, partners. milestone million commercial recognize pre-commercial License our or from clinical also we Strategic Platform
we have take the of As seriously. very agreements confidentiality our partnership previously we indicated,
to and So programs. SPL related development answer any our questions unable specific we'll their partners to be respective
stages, see as to been we our seen making XXXX. existing SPL generally can the clinical our over portfolio the may the progress year, the in we early we past say excited partners have have SPL However, I and see suggesting in about enter clinic are as clinic pivotal product continue that first progress the our programs trials, that later additional including commercial
to to proud and therapeutics be partners to their bring able patients. our extremely support advanced are to We efforts
long scope of and We MaxCyte if research expand new to SPL cell successful, in modalities of the cell part would continued therapies see term. invest types, our which have and the their including partners indications be
XX% end over is XX programs, entered greater And signed clinic. the covering total programs, have four billion, our entered potential XX $X.X to by $XXX XX to than XX% the pre-commercial of million XXXX. from revenue This the of total SPL had now which ongoing at early more one than in from more programs our The now signing including have are compares success which We up SPL the Production to term, SPL from generate the Intima in we XX than potential we than SPLs In agreement about to of our and January be XX clinic. well continues partners SPLs both our with clinical next XXXX. the XX with milestones as XXXX more have our covering last months. partners addition, XXXX. update in meaningful over progress, in expanding the near have revenue SPL base, for In further value validated customer as Biosciences agreements optimistic new the Research of
achieve to scientific into in success, continue candidates generation next moving clinical their partners particularly Our both trials. pivotal and product
partnership. refining relationships next progression potential was new also the We XXXX potential our details pipeline several vivo the see ex of variety types, cell years. the see in geographies, engineered long comparable a With customers to the the existing year, we the the our strategic ex representative announcements filings therapy novel Amanda by our expect recent engineered in partnerships, to cell strengthening see to in our few pre-commercial of SPL additional of for the our of term investing partnership approaches, value a focus investment SPL later we this for of The SPL plan. business and that expect year. will MaxCyte IND Much across economics over share prior to more partnerships and this and partners vivo indications brings around therapies space, SPL of commitment milestones to remain and cell ongoing continue
instrument VLx into on data customers the has disruptive investments VLx VLx be in for and ExPERT entered in will the have been product build scale brand beta feedback, the beta After large been we testing from in we alpha select bioprocessing we the several encouraged the scale by marketplace valuable large One seen and the we technology have ExPERT the XXXX. in applications up of believe testing bioprocessing customers VLx market the expansion applications. years XXXX, support which a program. plan receiving we released several with customers with the our interest has a under our to In to work participating to and
the large will in scale the bioprocessing market VLx evolve. While opportunity time the applications expansion to take for
We to are encouraged by the the to progress and updating product of on VLx look investors over date, the time. forward evolution roadmap
the assemblies fourth full use Finally, launched in for three which quarter. in new the disposables single we strengthen year business to and processing the continued particularly XXXX, core or
move as We are also partners investing closer the of commercial our manufacturing process development launch and to therapeutic in products.
year, into manufacturing our facility our plans than this capabilities. our and tripled a new which move more with track on are We space expands development to process
assemblies. key also We further process, to insource continue of particularly around the processing manufacturing elements
meaningfully a remain sales made XXXX maintaining progress strong strong are scaling in and substantial we we in MaxCyte’s and are our commercial of pace organization team, hiring Additionally, and scientist marketing committed including at field investing culture our to excellence.
We accelerate are commercial earlier us assessments, experience to MaxCyte’s also Cenk brings in collaborations Officer, innovation. Cenk and excited development and the month technology, Scientific join this deep of announce Sumen leading Chief scientific applications technical partnerships, to as and platform
marketing. we strategic we goals. continue most and to areas look development and research more financial had grow execute closing, and team XXXX, an sales particularly of to to our organization, MaxCyte expect we continue across we In XXXX As have as its into in the excellent
financial We forward, our we Amanda in that and right to across market, cell call now are are results. over about I will the the opportunity particularly drive discuss going making to our the very investments therapy excited growth the business. believe turn Amanda?